

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3880058

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALNYLAM PHARMACEUTICALS, INC.	12/05/2012
RECEIVING PARTY DATA	
Name:	TEKMIRA PHARMACEUTICALS CORPORATION
Street Address:	100-8900 GLENLYON PARKWAY
City:	BURNABY, BRITISH COLUMBIA
State/Country:	CANADA
Postal Code:	V5J 5J8
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15133010
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9528764083
Email:	mluedtke@vhpglobalip.com
Correspondent Name:	VIKSNINS HARRIS & PADYS PLLP
Address Line 1:	7851 METRO PARKWAY
Address Line 2:	SUITE 325
Address Line 4:	BLOOMINGTON, MINNESOTA 55425
ATTORNEY DOCKET NUMBER:	08050.004US3
NAME OF SUBMITTER:	YANG LI
SIGNATURE:	/Yang Li/
DATE SIGNED:	05/19/2016
Total Attachments: 10	
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page1.tif	
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page2.tif	
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page3.tif	
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page4.tif	
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page5.tif	

source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page6.tif
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page7.tif
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page8.tif
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page9.tif
source=08050.004US2-ASSIGNMENT TO BE FILED-ALN TO TEK0001#page10.tif


ASSIGNMENT

Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (hereinafter referred to as Assignor), for good and valuable consideration, has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto Tekmira Pharmaceuticals Corporation, a corporation organized and existing under the laws of British Columbia with its principal place of business at 100 - 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8 (hereinafter referred to as Assignee), its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the patents and patent applications set forth on Schedule 1 (attached hereto) (hereinafter referred to as the "Transferred Patents and Patent Applications"), including all priority rights therein, and in and to any and all divisions and continuations of the Transferred Patents and Patent Applications, and any and all Letters Patent in all countries throughout the world which may be granted therefor and thereon, and reissues and reexaminations of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property and the Patent Cooperation Treaty.

The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any Letters Patent resulting from the Transferred Patents and Patent Applications to the Assignee.

Alnylam Pharmaceuticals, Inc.

Date: December 5, 2012

By: 

Name: Steven A. Boscone

Title: Vice President, Intellectual Property

ACCEPTANCE BY ASSIGNEE

In connection with an assignment in any jurisdiction in which an acceptance by Assignee is required, I hereby accept this assignment on behalf of Tekmira Pharmaceuticals Corporation, I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that (check all that apply):

I am an officer of the above-identified Assignee,

I have signed this document on behalf of Assignee with the full authority of its board of directors,

and that all the foregoing is true and correct.

Tekmira Pharmaceuticals Corporation

Date: December 5, 2012

By: 

Print Name: Ian Mortimer

Title: Chief Financial Officer

Schedule 1

Alylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALCN-001	US	61/185800	10-Jun-2009		
ALCN-001	US	12/813448	10-Jun-2010	8158601	17-Apr-2012
ALCN-001	US	13/357856	25-Jan-2012		
ALN-109 (incorporated into ALCN- 001)	US	61/244834	22-Sep-2009		
ALCN-001	PCT	PCT/US2010/038224	10-Jun-2010		
ALCN-001	Australia	2010259984	10-Jun-2010		
ALCN-001	Canada	2764609	10-Jun-2010		
ALCN-001	China (People's Republic)	201080026228.8	10-Jun-2010		
ALCN-001	Eurasian Patent Organization	201190306	10-Jun-2010		
ALCN-001	European Patent Convention	10786869.7	10-Jun-2011		
ALCN-001	Israel	216876	10-Jun-2010		
ALCN-001	India	2646/MUMNP/2011	10-Jun-2010		
ALCN-001	Japan	2012-515160	10-Jun-2010		
ALCN-001	Korea, Republic of	10-2012-7000749	10-Jun-2010		
ALCN-001	Mexico	MX/A/2011/013320	10-Jun-2010		
ALCN-001	New Zealand	596958	10-Jun-2010		
ALCN-001	Singapore	201109154-3	10-Jun-2010		
ALCN-001	Hong Kong	12103989.3	10-Jun-2010		
ALCN-002	US	61/287995	18-Dec-2009		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALCN-002	PCT	PCT/US10/61058	17-Dec-2010		
ALCN-002	Australia	2010330814	17-Dec-2010		
ALCN-002	Canada	2784568	17-Dec-2010		
ALCN-002	European Patent Convention	10838298.7	17-Dec-2010		
ALCN-002	New Zealand	600725	17-Dec-2010		
ALCN-002	US	13/516335	15-Jun-2012		
ALN-040	US	60/828022	03-Oct-2006		
ALN-040	US	60/870457	18-Dec-2006		
ALN-040	US	12/056230	26-Mar-2008	8034376	11-Oct-2011
ALN-040	US	13/211094	16-Aug-2011		
ALN-040	PCT	PCT/US2007/080331	03-Oct-2007		
ALN-040	Australia	2007-303205	03-Oct-2007		
ALN-040	Canada	2665225	03-Oct-2007		
ALN-040	China (People's Republic)	200780044738.6	03-Oct-2007		
ALN-040	European Patent Convention	07853756.0	03-Oct-2007		
ALN-040	India	2211/DELNP/2009	03-Oct-2007		
ALN-040	Japan	2009-531586	03-Oct-2007		
ALN-040	Korea, Republic of	10-2009-7009148	03-Oct-2007	10-1129509	16-Mar-2012
ALN-040	Mexico	MX/a/2009/003548	03-Oct-2007		
ALN-040	Mexico	MX/a/2012/006901	03-Oct-2007		
ALN-050	US	61/018,616	02-Jan-2008		
ALN-050	US	61/018,611	02-Jan-2008		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-050	US	61/018,627	02-Jan-2008		
ALN-050	US	61/039,748	26-Mar-2008		
ALN-050	US	61/047,087	22-Apr-2008		
ALN-050	US	61/051,528	08-May-2008		
ALN-050	US	61/107,998	23-Oct-2008		
ALN-050	US	13/460963	01-May-2012		
ALN-050	PCT	PCT/US08/88588	31-Dec-2008		
ALN-050	PCT	PCT/US08/88587	31-Dec-2008		
ALN-050	PCT	PCT/US09/041442	22-Apr-2009		
ALN-050	PCT	PCT/US09/061897	23-Oct-2009		
ALN-050	Australia	2008347251	31-Dec-2008		
ALN-050	Australia	2008347250	31-Dec-2008		
ALN-050	Canada	2,711,240	31-Dec-2008		
ALN-050	Canada	2,711,236	31-Dec-2008		
ALN-050	US	12/811511	04-Nov-2010		
ALN-050	US	12/811503	01-Jul-2010		
ALN-050	US	12/989051	21-Oct-2010		
ALN-060	US	61/044,186	11-Apr-2008		
ALN-060	Australia	2009234266	10-Apr-2009		
ALN-060	European Patent Convention	09730178.2	10-Apr-2009		
ALN-060	US	12/936961	10-Apr-2009		
ALN-060	PCT	PCT/US09/40274	10-Apr-2009		
ALN-060	Canada	2,721,183	10-Apr-2009		
ALN-060	Japan	2011-504224	10-Apr-2009		
ALN-079	US	61/154350	20-Feb-2009		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-079	US	61/171439	21-Apr-2009		
ALN-079	US	61/185438	09-Jun-2009		
ALN-079	US	61/225898	15-Jul-2009		
ALN-079	US	61/234098	14-Aug-2009		
ALN-079	US	61/113179	10-Nov-2008		
ALN-079	US	13/211150	16-Aug-2011		
ALN-079	PCT	PCT/US09/63927	10-Nov-2009		
ALN-079	PCT	PCT/US09/63931	10-Nov-2009		
ALN-079	PCT	PCT/US09/63933	10-Nov-2009		
ALN-079	PCT	PCT/US09/63897	10-Nov-2009		
ALN-079	Australia	2009313201	10-Nov-2009		
ALN-079	Australia	2009313205	10-Nov-2009		
ALN-079	Australia	2009313206	10-Nov-2009		
ALN-079	Canada	2743135	10-Nov-2009		
ALN-079	Canada	2743136	10-Nov-2009		
ALN-079	Canada	2743139	20-Nov-2009		
ALN-079	China (People's Republic)	200980154346.4	10-Nov-2009		
ALN-079	China (People's Republic)	200980154380.1	11-Jun-2011		
ALN-079	Eurasian Patent Organization	201170553	10-Nov-2009		
ALN-079	Eurasian Patent Organization	201170554	10-Nov-2009		
ALN-079	European Patent Convention	09825614.2	10-Nov-2009		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-079	European Patent Convention	09825609.2	10-Nov-2009		
ALN-079	European Patent Convention	09825613.4	10-Nov-2009		
ALN-079	Israel	212801	10-Nov-2009		
ALN-079	Israel	212802	10-Nov-2009		
ALN-079	India	1948/KOLNP/2011	10-Nov-2009		
ALN-079	India	1947/KOLNP/2011	10-Nov-2009		
ALN-079	Japan	2011-535779	10-Nov-2009		
ALN-079	Japan	2011-535775	10-Nov-2009		
ALN-079	Japan	2011-535778	10-Nov-2009		
ALN-079	Korea, Republic of	10-2011-7013225	10-Nov-2009		
ALN-079	Korea, Republic of	10-2011-7013224	10-Nov-2009		
ALN-079	Mexico	MX/a/2011/004973	10-Nov-2009		
ALN-079	Mexico	MX/a/2011/004974	10-Nov-2009		
ALN-079	New Zealand	592767	10-Nov-2009		
ALN-079	New Zealand	592772	10-Nov-2009		
ALN-079	Singapore	201103330-5	10-Nov-2009		
ALN-079	Singapore	201103331-3	10-Nov-2009		
ALN-079	US	13/128283	10-Nov-2009		
ALN-079	US	13/128287	09-May-2011		
ALN-079	US	13/128363	26-Oct-2011		
ALN-079	US	13/128253	09-May-2011		
ALN-079	Hong Kong	12101632.8	17-Feb-2012		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-079	Hong Kong	12101776.4	22-Feb-2012		
ALN-085	US	61/148366	29-Jan-2009		
ALN-085	US	61/156851	02-Mar-2009		
ALN-085	US	61/185712	10-Jun-2009		
ALN-085	US	61/228373	24-Jul-2009		
ALN-085	US	61/239686	03-Sep-2009		
ALN-085	PCT	PCT/US2010/022614	29-Jan-2010		
ALN-085	Australia	2010208035	29-Jan-2010		
ALN-085	Canada	2751342	29-Jan-2010		
ALN-085	European Patent Convention	10703734.3	29-Jan-2010		
ALN-085	US	13/147189	29-Jan-2010		
ALN-089	US	61/187242	15-Jun-2009		
ALN-089	PCT	PCT/US10/38679	15-Jun-2010		
ALN-089	US	13/378346	15-Jun-2010		
ALN-095	US	61/175,770	05-May-2009		
ALN-095	US	61/299,291	28-Jan-2010		
ALN-095	PCT	PCT/US2010/033777	05-May-2010		
ALN-095	China (People's Republic)	201080020203.7	05-May-2010		
ALN-095	Australia	2010245869	05-May-2010		
ALN-095	Canada	2760776	05-May-2010		
ALN-095	China	201080020203.7	05-May-2010		
ALN-095	Eurasian Patent Organization	201190242	05-May-2010		

Alnylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-095	European Patent Convention	10772790.1	05-May-2010		
ALN-095	Israel	216142	05-May-2010		
ALN-095	India	2330/MUMNP/2011	05-May-2010		
ALN-095	Japan	2012-509956	05-May-2010		
ALN-095	Korea	10-2011-7026392	05-May-2010		
ALN-095	New Zealand	596186	05-May-2010		
ALN-095	Singapore	201108113-0	05-May-2010		
ALN-095	US	13/318600	05-May-2010		
ALN-095	Hong Kong	12102958.2	26-Mar-2012		
ALN-096	US	61/175777	05-May-2009		
ALN-096	US	61/234,045	14-Aug-2009		
ALN-096	US	61/242761	15-Sep-2009		
ALN-096	US	61/251991	15-Oct-2009		
ALN-096	US	61/258,848	06-Nov-2009		
ALN-096	US	12/774330	05-May-2010		
ALN-096	PCT	PCT/US2010/033747	05-May-2010		
ALN-096	Australia	2010245933	05-May-2010		
ALN-096	Canada	2760706	05-May-2010		
ALN-096	European Patent Convention	10772775.2	05-May-2010		
ALN-096	Japan	2012-509952	05-May-2010		
ALN-115	US	61/267419	07-Dec-2009		
ALN-115	US	61/334,398	13-May-2010		
ALN-115	US	61/384303	19-Sep-2010		

Alylam Ref. No.	Country	Application No.	Application Date	Patent No.	Grant Date
ALN-115	PCT	PCT/US2010/059206	07-Dec-2010		
ALN-115	Australia	2010328336	07-Dec-2010		
ALN-115	Canada	2783372	07-Dec-2010		
ALN-115	European Patent Convention	10836504.0	07-Dec-2010		
ALN-115	US	13/514352	07-Jun-2012		
ALN-129	US	61/321,829	07-Apr-2010		
ALN-129	US	61/369530	30-Jul-2010		
ALN-129	PCT	PCT/US2011/045963	29-Jul-2011		